Clinical implications of Wntpathway genetic alterations in men with advanced prostate cancer

Autor: Broderick, Amanda, Pan, Elizabeth, Li, Jinju, Chu, Alec, Hwang, Clara, Barata, Pedro C., Cackowski, Frank Cameron, Labriola, Matthew, Ghose, Alyssa, Bilen, Mehmet Asim, Kilari, Deepak, Thapa, Bicky, Piero, Michael, Graham, Laura, Tripathi, Abhishek, Garje, Rohan, Koshkin, Vadim S., Hernandez, Erik, Dorff, Tanya B., Schweizer, Michael Thomas, Alva, Ajjai Shivaram, McKay, Rana R., Armstrong, Andrew J.
Zdroj: Prostate Cancer and Prostatic Diseases; 20240101, Issue: Preprints p1-8, 8p
Abstrakt: Background: Aberrant Wnt signaling has been implicated in prostate cancer tumorigenesis and metastasis in preclinical models but the impact of genetic alterations in Wnt signaling genes in men with advanced prostate cancer is unknown. Methods: We utilized the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) clinical-genomic database for this retrospective analysis. Patients with activating mutations in CTNNB1or RSPO2or inactivating mutations in APC, RNF43, or ZNRF3were defined as Wnt-altered, while those lacking such alterations were defined as Wnt non-altered. We compared patient characteristics and clinical outcomes as well as co-occurring genetic alterations according to Wnt alteration status. Results: Of the 1498 patients included, 193 (12.9%) were Wnt-altered. These men had a statistically significant 2-fold increased prevalence of liver and lung metastases as compared with Wnt non-altered patients at the time of initial diagnosis, (4.66% v 2.15% ; 6.22% v 3.07%), first metastatic disease diagnosis (10.88% v 5.29%; 13.99% v 6.21%), and CRPC development (11.40% v 6.36%; 12.95% v 5.29%). Wnt alterations were associated with more co-occurring alterations in RB1(10.4% v 6.2%), AR(38.9% vs 25.7%), SPOP(13.5% vs 4.1%), FOXA1(6.7% vs 2.8%), and PIK3CA(10.9% vs 5.1%). We found no significant differences in overall survival or other clinical outcomes from initial diagnosis, first metastatic disease, diagnosis of CRPC, or with AR inhibition for mCRPC between the Wnt groups. Conclusions: Wnt-altered patients with prostate cancer have a higher prevalence of visceral metastases and are enriched in RB1, AR, SPOP, FOXA1, and PIK3CAalterations. Despite these associations, Wnt alterations were not associated with worse survival or treatment outcomes in men with advanced prostate cancer.
Databáze: Supplemental Index
Externí odkaz: